Literature DB >> 17507636

Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia.

Joli R Weiss1, Maria R Baer, Christine B Ambrosone, Javier G Blanco, Alan Hutson, Laurie A Ford, Kirsten B Moysich.   

Abstract

Archived tumor tissue is a useful resource for retrospective studies addressing relationships between genetic polymorphisms and treatment outcomes. However, genotypes determined in tumor and somatic tissues may differ due to cytogenetic and molecular changes associated with malignant transformation and progression. Discordance between germ line and tumor genotypes may be particularly relevant in leukemia because cytogenetic abnormalities are frequent. We compared genotypes determined in DNA extracted from paired pretreatment bone marrow and buccal samples from 80 adult patients with acute myeloid leukemia (AML). Paired AML and buccal DNA samples were genotyped for polymorphisms (21 single nucleotide polymorphisms and 2 gene deletions) on genes encoding proteins involved in drug metabolism (CYP3A4, CYP2C8, CDA, and GSTP1), oxidative stress mechanisms (CAT, MnSOD, GSTT1, GSTM1, GSTA1, and GPX1), drug transport (MDR1, MRP1, and BCRP), and DNA repair (MGMT, XPD, and XRCC1). Genotypes were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, except GSTM1 and GSTT1, for which deletion genotypes were determined using multiplex PCR. Concordance of genotypes was tested by kappa statistics. kappa statistics for paired AML and buccal DNA samples ranged between 0.94 and 1.00, indicating excellent agreement. The GSTT1 and GSTM1 genotypes were in perfect concordance for the paired samples. Agreement was also excellent for genes at AML chromosome deletion and translocation breakpoints, including MDR1 at 7q21.1 and MRP1 at 16p13.1. Based on these data, genotypes derived from archived AML bone marrow samples were not likely to differ from those from genomic DNA, and archived bone marrow samples may be useful for the conduct of retrospective pharmacogenetic studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507636     DOI: 10.1158/1055-9965.EPI-06-0964

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  13 in total

1.  XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls.

Authors:  Yi Huang; Denghai Xie; Nana Tang; Jishi Wang; Xiaoqing Zeng; Peng Zhao; Ling He
Journal:  Tumour Biol       Date:  2013-08-30

2.  Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.

Authors:  Heather L Gustafson; Song Yao; Bryan H Goldman; Kristy Lee; Catherine M Spier; Michael L LeBlanc; Lisa M Rimsza; James R Cerhan; Thomas M Habermann; Brian K Link; Matthew J Maurer; Susan L Slager; Daniel O Persky; Thomas P Miller; Richard I Fisher; Christine B Ambrosone; Margaret M Briehl
Journal:  Am J Hematol       Date:  2014-04-12       Impact factor: 10.047

3.  Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

Authors:  Chunqiao Tian; Christine B Ambrosone; Kathleen M Darcy; Thomas C Krivak; Deborah K Armstrong; Michael A Bookman; Warren Davis; Hua Zhao; Kirsten Moysich; Holly Gallion; Julie A DeLoia
Journal:  Gynecol Oncol       Date:  2011-11-21       Impact factor: 5.482

4.  ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients.

Authors:  Marcos Antonio Mauricio Scheiner; Flavia da Cunha Vasconcelos; Roberta Rodrigues da Matta; Reinaldo Dal Bello Figueira; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-23       Impact factor: 4.553

5.  Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Carol L Rosenberg; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Clin Epidemiol       Date:  2010-10-22       Impact factor: 4.790

6.  Polymorphisms in XPC provide prognostic information in acute myeloid leukemia.

Authors:  Peipei Xu; Baoan Chen; Jifeng Feng; Lu Cheng; Guohua Xia; Yufeng Li; Jun Qian; Jiahua Ding; Zuhong Lu
Journal:  Int J Hematol       Date:  2012-09-12       Impact factor: 2.490

7.  Maternal smoking and oral clefts: the role of detoxification pathway genes.

Authors:  Rolv T Lie; Allen J Wilcox; Jack Taylor; Håkon K Gjessing; Ola Didrik Saugstad; Frank Aabyholm; Halvard Vindenes
Journal:  Epidemiology       Date:  2008-07       Impact factor: 4.822

Review 8.  Using germline genotype in cancer pharmacogenetic studies.

Authors:  Sarah R McWhinney; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

9.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Authors:  James M Rae; Suzy Drury; Daniel F Hayes; Vered Stearns; Jacklyn N Thibert; Ben P Haynes; Janine Salter; Ivana Sestak; Jack Cuzick; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

10.  High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues.

Authors:  M J Sikora; J N Thibert; J Salter; M Dowsett; M D Johnson; J M Rae
Journal:  Pharmacogenomics J       Date:  2010-06-15       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.